Septerna (SEPN)

Executive Summary

Septerna is a clinical-stage biotechnology company leveraging its proprietary Native Complex Platform® to develop oral small molecule medicines targeting G protein-coupled receptors (GPCRs). The company's pipeline focuses on endocrinology, immunology/inflammation, and metabolic diseases. Currently, Septerna has two Phase 1 trials ongoing: SEP-479 and SEP-631, both in healthy volunteers. SEP-631 is expected to complete by April 2026, while SEP-479 is slated for completion in early 2027. Despite early-stage readouts, the company's platform approach to GPCRs—a historically challenging but highly validated drug target class—positions it for potential differentiation. As a public company with a market cap of ~$1.6B, Septerna has attracted attention for its novel platform and pipeline, though no late-stage data are yet available. Investors will closely monitor initial safety and pharmacokinetic data from these Phase 1 studies to validate the platform and inform future development.

Upcoming Catalysts (preview)

• Q2 2026Phase 1 completion and topline data for SEP-631 in healthy volunteers70% success
• Q1 2027Phase 1 interim or full data for SEP-479 in healthy volunteers65% success
• H2 2026Potential preclinical updates or new pipeline candidate disclosures50% success